KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Profit After Tax (2016 - 2026)

Pfizer has reported Profit After Tax over the past 18 years, most recently at $2.7 billion for Q1 2026.

  • Quarterly Profit After Tax fell 8.7% to $2.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.5 billion through Mar 2026, down 28.9% year-over-year, with the annual reading at $7.8 billion for FY2025, 3.04% down from the prior year.
  • Profit After Tax was $2.7 billion for Q1 2026 at Pfizer, up from -$1.6 billion in the prior quarter.
  • Over five years, Profit After Tax peaked at $9.9 billion in Q3 2022 and troughed at -$2.4 billion in Q4 2023.
  • The 5-year median for Profit After Tax is $2.8 billion (2025), against an average of $2.7 billion.
  • Year-over-year, Profit After Tax crashed 127.55% in 2023 and then soared 6997.56% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $225.0 million in 2022, then crashed by 73.33% to $60.0 million in 2023, then skyrocketed by 7341.67% to $4.5 billion in 2024, then crashed by 136.55% to -$1.6 billion in 2025, then surged by 265.99% to $2.7 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Profit After Tax are $2.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and $3.6 billion (Q3 2025).